Alteogen Inc
KOSDAQ:196170
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
67 800
445 500
|
Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Alteogen Inc
Cash & Cash Equivalents
Alteogen Inc
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Alteogen Inc
KOSDAQ:196170
|
Cash & Cash Equivalents
â‚©27B
|
CAGR 3-Years
15%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
||
Celltrion Inc
KRX:068270
|
Cash & Cash Equivalents
â‚©564.6B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
5%
|
CAGR 10-Years
30%
|
||
SK Bioscience Co Ltd
KRX:302440
|
Cash & Cash Equivalents
â‚©127B
|
CAGR 3-Years
72%
|
CAGR 5-Years
95%
|
CAGR 10-Years
N/A
|
||
Green Cross Corp
KRX:006280
|
Cash & Cash Equivalents
â‚©44.9B
|
CAGR 3-Years
-37%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
9%
|
||
H
|
Hugel Inc
KOSDAQ:145020
|
Cash & Cash Equivalents
â‚©182.9B
|
CAGR 3-Years
61%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
P
|
PharmaResearch Co Ltd
KOSDAQ:214450
|
Cash & Cash Equivalents
â‚©78.4B
|
CAGR 3-Years
51%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
Alteogen Inc
Glance View
Alteogen Inc. is a biopharmaceutical company based in South Korea that has carved out a niche in the development of innovative drug delivery systems. Founded in 2005, the company specializes in the creation of biosimilars and biobetters – biologic drugs that improve upon existing therapies. With a strong pipeline aimed at addressing critical unmet medical needs, Alteogen focuses on therapeutic areas such as oncology, autoimmune diseases, and chronic conditions. One of their standout innovations is the proprietary technology for enhanced antibody-drug conjugates, which can significantly improve the efficacy and safety profiles of existing treatments. As the global demand for advanced therapeutics continues to rise, Alteogen presents a compelling story of potential growth driven by scientific innovation. For investors, Alteogen’s strategic partnerships and collaboration with major pharmaceutical companies amplify its growth trajectory. The company is not only positioned to benefit from its proprietary technologies but is also shaping its portfolio to align with the growing market for biosimilars. As competition in the biopharmaceutical space intensifies, Alteogen’s commitment to research and development sets it apart, showcasing its dedication to delivering next-generation medicines. With a robust clinical development pipeline and strong market momentum, Alteogen Inc. represents an intriguing opportunity for investors looking to tap into the evolution of healthcare and the future of targeted therapies.
See Also
What is Alteogen Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
27B
KRW
Based on the financial report for Sep 30, 2024, Alteogen Inc's Cash & Cash Equivalents amounts to 27B KRW.
What is Alteogen Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
22%
Over the last year, the Cash & Cash Equivalents growth was 21%. The average annual Cash & Cash Equivalents growth rates for Alteogen Inc have been 15% over the past three years , 22% over the past five years .